Brimonidine Tartrate

Derick, Robert J.; Robin, Alan L.; Walters, Thomas R.; Barnebey, Howard S.; Choplin, Neil T.; Schuman, Joel S.; Kelley, Elaine P.; Chen, Kuankuan; Stoecker, Jack F.

doi:10.1016/s0161-6420(97)30349-2

Cited by 125 publications

(24 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In previous studies it was shown that the cardiopulmonary effects of brimonidine 0.2% were limited to a slight reduction in systemic blood pressure [9, 10, 11, 12]. This suggests that, like all other topical glaucoma medications, brimonidine is absorbed systemically.…”

Section: Discussionmentioning

confidence: 98%

“…Tachyphylaxis and ocular allergy have been reported with apraclonidine [23, 24]. Tachyphylaxis was not observed with brimonidine; the incidence of ocular allergy with brimonidine was reported to be less than with apraclonidine [10, 11, 12, 21, 22, 25]. The differences between brimonidine and apraclonidine may be related to differences in chemical structures and in selectivity for the α-adrenoceptors.…”

Section: Discussionmentioning

confidence: 99%

“…It appears to lower IOP in humans through a reduction of aqueous humor inflow and by an increase in uveoscleral outflow [8]. Clinical studies have been performed for acute indications using the 0.5 % concentration and for chronic indications using the 0.2% concentration [9, 10, 11]. Dose-response studies have found brimonidine 0.2% twice daily to be safely and effectively lowering IOP in patients with open-angle glaucoma or ocular hypertension [12].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The Short-Term Effect of Adding Brimonidine 0.2% to Timolol Treatment in Patients with Open-Angle Glaucoma

Yüksel

Altıntaş²,

Karabaş³

et al. 1999

Ophthalmologica

View full text Add to dashboard Cite

Brimonidine, a highly selective α₂-adrenoceptor agonist, was studied to determine its ocular hypotensive effect and side effects in patients with elevated intraocular pressure (IOP) while on continuing therapy with timolol. This was a prospective, randomized, placebo-controlled study in 15 patients with primary open-angle or pseudoexfoliation glaucoma on therapy receiving timolol 0.5% twice daily, with IOP greater than or equal to 22 mm Hg in one eye. IOP measurements, blood pressure and pulse rate were assessed on 2 days at a baseline and 1, 2, 4, 6 and 8 h later. A single drop of brimonidine 0.2% or placebo was added to treatment with timolol. The reductions in IOP at all time intervals observed with brimonidine + timolol were significantly greater than those with timolol + placebo. The maximum mean net decrease in IOP was 19.23 ± 10.60% at 4 h. Statistically significant decreases in systemic blood pressure and pulse rate without clinical symptoms were observed in the group receiving brimonidine + timolol. This study suggests that a combination of brimonidine and timolol may have potential in the treatment of glaucoma. Further clinical trials with brimonidine are indicated to assess its further role as adjunctive agent.

show abstract

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Short-Term Effect of Adding Brimonidine 0.2% to Timolol Treatment in Patients with Open-Angle Glaucoma

Yüksel

Altıntaş²,

Karabaş³

et al. 1999

Ophthalmologica

View full text Add to dashboard Cite

show abstract

“…It lowers IOP in humans and appears to do this through the reduction of aqueous humor inflow and increase in uveoscleral outflow [12]. Brimonidine is an effective agent in reducing elevations in IOP after anterior segment laser surgery [13].…”

Section: Introductionmentioning

confidence: 99%

“…Brimonidine (0.2%) is well-tolerated, safe and more effective than 0.25% betaxolol in lowering IOP in patients with elevated IOP [14]. In addition, its effects on heart rate and systemic blood pressure are minimal [12, 14, 15]. …”

Section: Introductionmentioning

confidence: 99%

A Comparison of the Short-Term Hypotensive Effects and Side Effects of Unilateral Brimonidine and Apraclonidine in Patients with Elevated Intraocular Pressure

Yüksel

Karabaş²,

Altıntaş³

et al. 2002

Ophthalmologica

View full text Add to dashboard Cite

Purpose: To compare the short-term ocular hypotensive efficacy and side effects of 0.2% brimonidine and 0.5% apraclonidine in patients with elevated intraocular pressure (IOP). Methods: We performed a double-masked, placebo-controlled study to compare the efficacy of the application of 0.2% brimonidine and 0.5% apraclonidine for the effect of IOP, systemic blood pressure and heart rate in 20 newly diagnosed ocular hypertensive patients. Effects on the untreated fellow eye and ocular side effects were also determined. All measurements were performed 1, 2, 4, 6 and 8 h after the instillation of one drop. Results: Brimonidine and apraclonidine significantly reduced IOP from baseline at all observation times. No significant difference was observed between the treatment groups. IOP decreased significantly in the untreated fellow eye in the brimonidine group at 4-, 6- and 8-hour checks and at 6-hour checks in the apraclonidine group when compared with placebo. Blood pressure and heart rate decreased significantly in the brimonidine group compared with placebo. Apraclonidine did not affect blood pressure or heart rate any differently than placebo. The pupil diameter and the interpalpebral fissure width significantly increased in the apraclonidine group, but not in the brimonidine group. There were no significant differences in the overall incidence of foreign body sensation, burning and stinging and dry mouth in the treatment groups. Conclusions: In the short-term, brimonidine was effective in reducing IOP in patients with elevated IOP and was equivalent in efficacy to apraclonidine. On the other hand, a significant change in blood pressure and heart rate was observed with brimonidine; there was no change at all in the apraclonidine group.

show abstract

Comparison of the Efficacy of Apraclonidine and Brimonidine as Aqueous Suppressants in Humans

Schadlu

Maus²,

Nau³

et al. 1998

Arch Ophthalmol

View full text Add to dashboard Cite

To measure and compare the effect of apraclonidine hydrochloride and brimonidine tartrate on the rate of aqueous humor flow in human subjects.Subjects and Methods: Forty normal human subjects were given apraclonidine or brimonidine by topical instillation. Aqueous humor flow was measured by the rate of disappearance of topically applied fluorescein. Intraocular pressure was measured by applanation tonometry.Results: Apraclonidine suppressed aqueous humor flow between 39% and 44% and lowered intraocular pressure between 20% and 23%. Brimonidine suppressed aqueous humor flow between 44% and 48% and lowered intraocular pressure between 19% and 22%. Conclusion:No statistically significant differences were found between the effects of the 2 drugs on aqueous humor dynamics in normal subjects.

show abstract

Brimonidine Tartrate

Cited by 125 publications

References 16 publications

The Short-Term Effect of Adding Brimonidine 0.2% to Timolol Treatment in Patients with Open-Angle Glaucoma

The Short-Term Effect of Adding Brimonidine 0.2% to Timolol Treatment in Patients with Open-Angle Glaucoma

A Comparison of the Short-Term Hypotensive Effects and Side Effects of Unilateral Brimonidine and Apraclonidine in Patients with Elevated Intraocular Pressure

Comparison of the Efficacy of Apraclonidine and Brimonidine as Aqueous Suppressants in Humans

Contact Info

Product

Resources

About